Bob,
Thanks for posting this abstract. When I spoke with Dr. Rozen in October of last year, he wasn't sure if he had collected sufficient data to submit an article on his pilot study and have it accepted. It appears he obtained one more study participant and that was sufficient...
Hopefully, Royce Fishman will be able to provide CH.com with the full text of Dr. Rozen's pilot study now that it's been published.
Those of you who have followed the saga behind Dr. Rozen's study, know that Michael Berger and I had it in the planning stage in 2007 and that Royce, Michael and I helped obtain the funding to make this pilot study possible.
The wonderful part of all this is we now have the results of a cluster headache study, published on oxygen therapy at flow rates much higher than 15 liters/minute, by one of the top neurologists in the US. This can and will start making a difference in how neurologists treat people with this disorder...
Now that Dr. Rozen has published the results of his pilot study, I'm no longer bound by my agreement with him not to disclose the details of the pilot study of this method oxygen therapy that Michael Berger and I conducted 2007-2008 with 7 CH'ers.
The study protocol that Dr. Rozen used in his pilot study is similar to that used in the RCTs for StatDose Imitrex (sumatriptan succinate injections). Both protocols called for only one dose (or application of oxygen therapy). These studies were both interventional, non-randomized and open label in design.
Dr. Rozen's demand valve pilot study and the StatDose Imitrex RCTs also used a similar primary outcome measure of percent pain free by 30 minutes, but collected data on all actual abort times. Dr. Rozen's pilot study also used an active comparator (oxygen therapy at a flow rate of 15 liters/minute).
you can read the entire protocol and secondary outcome measures used in Dr. Rozen's pilot study at the following link:
Multimedia File Viewing and Clickable Links are available for Registered Members only!! You need to

or

The rationale for the similar protocols was to provide an apples to apples comparison of the effectiveness of these two acute treatments of cluster headache.
The protocol that Michael and I used in our pilot study was somewhat different in design and intent. We encouraged participants to start this method of oxygen therapy at the first indication of a cluster headache.
In contrast, Dr. Rozen's protocol had the CH'er wait until the pain was moderate before starting the demand valve therapy. There are many of us here at CH.com who will tell you this is a sure recipe for much longer abort times.
We had participants use oxygen therapy at flow rates that support hyperventilation using either an oxygen demand valve or 0-60 liter/minute regulator equipped with an O2PTIMASK™ kit.
The O2PTIMASK users followed a sequence of flow rates consisting of 30 seconds each at 25 liters/minute, 40 liters/minute, and 60 liters/minute before returning to 40 liters/minute and staying at this flow rate until the abort. Participants collected abort time and pain level data on every cluster headache for 8 weeks.
Both applications of this method of oxygen therapy are based on the procedures I developed in 2005 and both are equally effective.
In 2007, Michael and I modified the procedures I developed in 2005 to work with oxygen demand valves and regulators provided by Royce Fishman, who was working for Linde LifeGas at the time. Dr. Rozen's pilot study used the exact same demand valve method of procedure.
The basic procedure requires the cluster headache sufferer to hyperventilate with 100% oxygen until they experience respiratory alkalosis with symptoms of paresthesia, and to continue hyperventilating at a high enough rate to maintain these symptoms until the abort to a completely pain free state.
All seven cluster headache sufferers (one woman, six men; one episodic CH'er, six chronic CH'ers) consulted with their PCP or neurologist before participating in this pilot study.
Participants were also allowed to use a bailout or escape abortive like an imitrex StatDose injection after 30 minutes if needed and at any time during the attempted abort if they felt they would be unable to continue with this method of oxygen therapy due to pain. Participants were also allowed to use prescribed cluster headache preventative medications and any other medications prescribed for other medical conditions.
Although the use of cluster headache preventatives may have had a slight influence, the results we obtained from this method of oxygen therapy were so stunning, it's unlikely the use of preventatives was a factor.
Ten CH'ers started our pilot study. Two episodic CHe'rs reached end of cycle after less than 10 days and dropped out. Another chronic CH'er dropped out of this pilot study due to an unrelated medical condition.
In all, seven CH'ers completed the 8 week study collecting data on 367 aborts using oxygen therapy at flow rates that support hyperventilation.
366 of these attempts resulted in a pain free abort prior to 30 minutes (25 minutes) for a raw efficacy of 99.7%. The average abort time for the 366 aborts was 7 minutes for cluster headaches ranging in pain levels 3 through 9 on the 10-Point Headache Pain Scale.
We included the one failed abort in the efficacy calculation in order to maintain objectivity. What happened was the CH'er went out for a walk and got hit five minutes from home and his oxygen...
When he returned home, he found his wife had gone shopping and locked all the doors. He didn't have his keys so he finally had to break a window to get to his oxygen...
By then his cluster headache had reached 10 on the 10-Point headache pain scale. He started this method of oxygen therapy and stayed with it for 30 minutes before using a StatDose injection of imitrex.
The following chart illustrates a plot of the actual abort times:
Multimedia File Viewing and Clickable Links are available for Registered Members only!! You need to

or

You'll find a black and white version of this chart in the patent Michael, Royce and I submitted to the USPTO on the Demand Valve Method of aborting CH in June of 2008. This application was published in 2010 and the patent issued in March of 2012. See the following link for more details on this patent:
Multimedia File Viewing and Clickable Links are available for Registered Members only!! You need to

or

As you can see in the chart above, we also used oxygen therapy at a flow rate of 15 liters/minute as an active comparator.
However, after the first pilot study participant completed collecting abort data at 15 liters/minute and started collecting data on the demand valve method of oxygen therapy, we found the dramatic reduction in abort times made possible with this new method of oxygen therapy were so significant, it made use of oxygen therapy at a flow rate of 15 liters/minute appear cruel and inhumane in comparison. Accordingly only 35 aborts were logged at a flow rate of 15 liters/minute. No other participants were asked to collect abort data at this flow rate.
Our study protocol, with abort data collected on every abort over an 8-week period, also made it possible for us to discover the direct relationship and positive correlation between time to abort and cluster headache pain level. The protocol used by Dr. Rozen, could not have discovered this phenomenon.
As you can see, higher cluster headache pain levels require longer abort times. The message here should be clear... starting oxygen therapy at the first indication of an attack will result in shorter abort times... or the longer you wait, the higher the pain level and the longer it's going to take to abort.
Even though this method of oxygen therapy requires significantly higher oxygen flow rates than traditionally prescribed, the seven participants in this pilot study averaged 25 aborts (min=19, max=30) from an M-size oxygen cylinder holding 3995 liters of oxygen.
At an average cost of $30 for an M-size oxygen cylinder refill before insurance, the average cost of oxygen consumed during each abort was $1.20.
Given the abort times between a StatDose of imitrex and the Demand Valve Method of Oxygen Therapy are not significantly different, cost per abort becomes a discriminator. Moreover, when you factor in the potential side effects from sumatriptan succinate and limitations on it's use compared to none for this method of oxygen therapy, there's a clear advantage to using oxygen therapy at flow rates that support hyperventilation as the first abortive of choice while at home, at work, or during local travel in your car.
One of the most significant findings of both pilot studies deals with the role of CO2 in cluster headache pathogenesis (triggering) and abort mechanisms. To date, there's been no mention or discussion of CO2 or its role in any scholarly paper or RTC results published on cluster headache.
In short, hyperventilating with 100% oxygen blows off CO2 faster than it's being generated by normal metabolism. This enables a very rapid and significantly greater level of vasoconstriction resulting in cluster headache abort times three to four times shorter than breathing oxygen at a flow rate of 15 liters/minute.
I'll be submitting an article with the complete findings, results and analysis of our pilot study of oxygen therapy at flow rates that support hyperventilation in the near future. Once it's published, I'll post a copy here at CH.com.
As always, I'll continue to answer questions on oxygen therapy as I have all along since joining this forum in 2006.
Take care,
V/R, Batch